Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection?

Pribylova, O.; Petruželka, Luboš; Shumansky, Karey; Spinelli, John J.; Ragaz, Joseph

doi:10.1200/jco.2005.23.16_suppl.818

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2012

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 11 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tables 2-4 summarize the trial eligibility criteria and outcomes. One abstract [62] could not be included due to the incomprehensible nature of the report.…”

Section: Resultsmentioning

confidence: 99%

HER2/neu in systemic therapy for women with breast cancer: a systematic review

Dhesy-Thind

Pritchard

Messersmith

et al. 2007

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Tables 2-4 summarize the trial eligibility criteria and outcomes. One abstract [62] could not be included due to the incomprehensible nature of the report.…”

Section: Resultsmentioning

confidence: 99%

HER2/neu in systemic therapy for women with breast cancer: a systematic review

Dhesy-Thind

Pritchard

Messersmith

et al. 2007

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Gastrointestinal stromal tumor: 5 years later

Zwan

DeMatteo

2005

Cancer

188

152

View full text Add to dashboard Cite

There is now considerable interest in gastrointestinal stromal tumor (GIST) because it can be treated effectively with a targeted molecular agent. The majority of GISTs contain an activating mutation in the KIT protooncogene or, occasionally, in the platelet-derived growth factor-␣ (PDGFRA) gene. Five years ago, imatinib mesylate, a specific molecular inhibitor of the protein products of these 2 genes, was applied to metastatic GIST. Approximately 80% of patients with metastatic GIST benefit from imatinib, although acquired resistance to the agent may develop. For patients with primary GIST, surgery remains the treatment of choice, and whether outcome is improved by adjuvant imatinib is currently under broad investigation. A combination of imatinib therapy and surgery also may be effective in a subset of patients with metastatic or unresectable primary GIST. In this review, the authors summarize the new multimodality approach to GIST. The integration of surgery and molecular therapy in GIST will serve as a prototype for the man-

show abstract

Biomarkers in GIST

Lim¹,

Blanke²

2012

Biomarkers in Oncology

View full text Add to dashboard Cite

Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection?

Cited by 11 publications

References 0 publications

HER2/neu in systemic therapy for women with breast cancer: a systematic review

HER2/neu in systemic therapy for women with breast cancer: a systematic review

Gastrointestinal stromal tumor: 5 years later

Biomarkers in GIST

Contact Info

Product

Resources

About